|
Daily Medical Update
Raynaud phenomenon
Thursday, September 03, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Circulation (2026) - Scientific Statement
Key Findings
- Secondary RP carries increased risk of digit ischemia or tissue loss, unlike the generally benign course of primary RP.
- Advanced imaging may improve earlier detection of secondary RP, and treatment of the underlying disease is emphasized to improve vascular symptoms and prevent complications.
📋 Practice Implication: Use the primary-versus-secondary distinction to guide connective-tissue-disease evaluation, risk counselling, and referral decisions.
|
Seminars in arthritis and rheumatism (2026) - Cross-sectional study
Key Findings
- Pre-SSc fingertip perfusion was lower than in healthy controls (139 ± 12 vs 200 ± 12 perfusion units; mean difference 61, 95% CI 38-85; p < 0.001).
- NVC demonstrated reduced capillary density (7.8 vs 9.8/mm, p < 0.001) and increased microhemorrhages (18% vs 7.4%, p = 0.032), with giant capillaries and a scleroderma pattern confined to pre-SSc patients.
- HFUS showed increased mean dermal thickness in pre-SSc, including differences at both fingers and the left forearm.
📋 Practice Implication: In specialist assessment of RP with suspected early systemic sclerosis, combining perfusion, capillaroscopy, and dermal imaging may uncover clinically silent microvascular disease.
|
Rheumatology international (2026) - Retrospective analysis
Key Findings
- Over a median 23-year follow-up, 832 of 2922 patients died, and mortality was increased compared with a demographically matched reference population (log-rank p < 0.001).
- In female patients with RP, ANA, anti-Scl-70, and grouped capillary abnormalities were associated with increased all-cause mortality; the highest mortality occurred when abnormal capillaries and ANA were both present.
📋 Practice Implication: Abnormal nailfold capillaries and ANA identify a higher-risk subgroup in incident RP and support intensified longitudinal risk assessment and specialist follow-up.
|
International journal of hyperthermia (2026) - Randomized controlled trial
Key Findings
- Pain decreased from 70.4 ± 27.8 to 56.7 ± 21.4 mm with wIRA and from 73.9 ± 27.5 to 65.3 ± 26.8 mm with control therapy; adjusted between-group mean difference was -14.7 mm (95% CI -28.8 to -0.7; p = 0.041).
- RP duration improved more with wIRA (β = -3.8, 95% CI -7.4 to -0.2; p = 0.041), while frequency, intensity, HAQ, IL-6, and VEGF did not differ significantly.
- No adverse events occurred during the study, with no increase in reported adverse-event burden.
📋 Practice Implication: For severe systemic-sclerosis RP already receiving iloprost and CO2 baths, wIRA is a potentially safe short-term adjunct for pain and attack duration, pending larger trials.
|
Asian Pacific journal of allergy and immunology (2025) - Randomized controlled trial
Key Findings
- Bosentan significantly reduced the occurrence of new digital ulcers compared with nifedipine over 16 weeks.
- Bosentan reduced pulmonary arterial hypertension symptoms and systolic pulmonary arterial pressure more than nifedipine.
- Raynaud Condition Score did not improve in the bosentan group at week 16, and headache was the most common adverse event in both groups.
📋 Practice Implication: Bosentan's value in this cohort was prevention of new ulcers and pulmonary vascular improvement rather than relief of Raynaud symptom scores, so treatment goals should be specified.
|
|
💡
Summary
Recent high-significance evidence reinforces that secondary Raynaud phenomenon is the higher-risk phenotype: the AHA statement links it to digit ischemia or tissue loss, and 23-year follow-up associated abnormal nailfold capillaries and ANA with excess mortality. In pre-systemic sclerosis Raynaud phenomenon, multimodal imaging detected structural and perfusion abnormalities. In systemic sclerosis, adjunctive wIRA modestly improved short-term pain and attack duration, while bosentan reduced new digital ulcers and pulmonary vascular measures but did not improve Raynaud symptom scores.
|
|